If the laser focus on getting to Nasdaq has caused the lack of transparency, I'd say that was a poor strategic decision.
Maybe it was a combination of factors but all the uncertainty combined with 'trust me' is a pretty hard sell to the market. As most people understand the market doesn't like uncertainty.
Maybe one of the problems is that this really is an OTC company until it is able to prove TO THE MARKET that it isn't ,and management refuses to accept that reality. We really have no validation otherwise.
One way they could have attempted to prove it to the market would have been to get that joint PR from Oracle.
Another would have been to get reviews of their products from industry professionals - Rich Bohn and others.
Another way would be to get an independant review of the company with a price valuation on it. You know by a company with real credentials to say what we are told the institutions already understand.
To blame the price on shorts is just naive. Yes, shorts affected the price, but they only did that because they knew that there wasn't enough confidence in the company to overcome them. The company IMO did not try hard enough to gain the confidence in ways such as I mention above. It is ridiculous IMO that we've been waiting for the Rich Bohn review now for over a year, for example.
So maybe in fact the strategy is to ball it up all together to get one final push to get to Nasdaq, but it didn't have to come with all this drama and pain if the OTC participants had been given a little more credit. I could be wrong. It's just how I see it.
News 
Market Data 
Discover 
